Sanofi fined for smear campaign against generic Plavix
This article was originally published in Scrip
Executive Summary
Sanofi has been fined €40.6 million by the French competition authority for abusing a dominant market position to run a smear campaign against generic versions of its blockbuster antithrombotic Plavix (clopidogrel).